Experts are excitedly focused on retatrutide, a innovative treatment developed by Eli Lilly, as a possible advance in weight management. Different than many existing approaches, retatrutide is a double -action agonist targeting both GLP-1 and GIP, chemicals that affect satiety and blood sugar balan